NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation A
NanoViricides, Inc. (NYSE: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC). NanoViricides has already put together a team with a renowned Principal Investigator and with support from a well known University in the Ebola-affected region for the execution of this clinical trial after regulatory approvals. NanoViricides' proposal for the said clinical trial has been approved by the Pillar Committee in Charge in the DRC. The DRC has reported a rapidly expanding number of confirmed cases at 1,561 with 506 confirmed deaths as of July 6, from more than 1,400 cases and 438 deaths reported as o...
NanoViricides, Inc. (NYSE: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC).
NanoViricides has already put together a team with a renowned Principal Investigator and with support from a well known University in the Ebola-affected region for the execution of this clinical trial after regulatory approvals.
NanoViricides' proposal for the said clinical trial has been approved by the Pillar Committee in Charge in the DRC.
The DRC has reported a rapidly expanding number of confirmed cases at 1,561 with 506 confirmed deaths as of July 6, from more than 1,400 cases and 438 deaths reported as of July 2.